1276:HKEXJiangsu Hengrui Pharmaceuticals Co.,Ltd Analysis
Data as of 2026-07-29 - not real-time
HK$58.30
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
The stock is trading just above its short‑term moving averages, with the 20‑day SMA closely matching the current price and a modestly bullish MACD histogram, suggesting limited upside momentum in the near term. RSI sits near the midpoint, indicating neither overbought nor oversold conditions, while volume trends are trending lower, hinting at waning short‑term enthusiasm.
Fundamentally, the company delivers robust revenue growth and exceptionally high gross and operating margins, underpinned by a massive cash pile and minimal debt, which supports a sustainable dividend despite the modest yield. However, the market price is well above the DCF‑derived fair value and the sector‑adjusted PE is notably higher than peers, leading analysts to flag the stock as overvalued even as consensus remains strongly positive, and market sentiment is at an extreme greed level.
Fundamentally, the company delivers robust revenue growth and exceptionally high gross and operating margins, underpinned by a massive cash pile and minimal debt, which supports a sustainable dividend despite the modest yield. However, the market price is well above the DCF‑derived fair value and the sector‑adjusted PE is notably higher than peers, leading analysts to flag the stock as overvalued even as consensus remains strongly positive, and market sentiment is at an extreme greed level.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Technical indicators show a neutral to slightly bullish stance
- Current valuation exceeds intrinsic estimates
- Decreasing volume suggests limited short‑term buying pressure
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Sustained revenue growth and high profitability margins
- Strong cash generation and low leverage
- Analyst consensus of strong‑buy despite valuation premium
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Long‑term pipeline in oncology and specialty therapeutics
- Consistent dividend payout with ample cash reserves
- Resilient ROE and ROA indicating durable competitive advantage
Key Metrics & Analysis
Financial Health
Revenue Growth13.00%
Profit Margin24.93%
P/E Ratio41.3
ROE14.54%
ROA8.80%
Debt/Equity0.10
P/B Ratio5.3
Op. Cash FlowHK$11.5B
Free Cash FlowHK$6.3B
Industry P/E30.1
Technical Analysis
TrendNeutral
RSI52.4
SupportHK$54.05
ResistanceHK$62.80
MA 20HK$58.22
MA 50HK$57.36
MA 200HK$67.66
MACDBullish
VolumeDecreasing
Fear & Greed Index88.88
Valuation
Fair ValueHK$27.15
Target PriceHK$94.65
Upside/Downside62.35%
GradeOvervalued
TypeGrowth
Dividend Yield0.40%
Risk Assessment
Beta-0.01
Volatility44.12%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.